Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells

Molecular and Cellular Biology

Volumn 26, Issue 17, 2006, Pages 6333-6346

  Sands, William A ^a   Woolson, Hayley D ^a   Milne, Gillian R ^a   Rutherford, Claire ^a   Palmer, Timothy M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ADENYLATE CYCLASE ACTIVATOR; ANTIPORTER; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; G PROTEIN COUPLED RECEPTOR; GLYCOPROTEIN GP 130; GUANINE NUCLEOTIDE EXCHANGE FACTOR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PROTEIN EPAC; PROTEIN INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 2; RAP1 PROTEIN; SMALL INTERFERING RNA; STAT PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME ACTIVITY; FIBROBLAST; HUMAN; HUMAN CELL; KNOCKOUT GENE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

3T3 CELLS; ANIMALS; CELLS, CULTURED; CHEMOKINE CCL2; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; ENDOTHELIAL CELLS; GENE EXPRESSION REGULATION; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; INTERLEUKIN-6; JANUS KINASE 1; MICE; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; RECEPTORS, INTERLEUKIN-6; RNA, MESSENGER; SIGNAL TRANSDUCTION; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS;

MURINAE;

EID: 33747749486     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.00207-06     Document Type: Article

References (59)

1. Aird, W. C. 2005. Spatial and temporal dynamics of the endothelium. J. Thromb. Haemost. 3:1392-1406.
2. Alexander, W. S., and D. J. Hilton. 2004. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22:503-529.
3. Blanchard, F., W. Yanping, E. Kinzie, L. Duplomb, A. Godard, and H. Baumann. 2001. Oncostatin M regulates the synthesis and turnover of gp130, leukemia inhibitory factor receptor a, and oncostatin M receptor-β by distinct mechanisms. J. Biol. Chem. 276:47038-47045.
4. Blease, K., A. Burke-Gaffney, and P. G. Hellewell. 1998. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4. Br. J. Pharmacol. 124:229-237.
5. Bos, J. L. 2003. Epac: a new cAMP target and new avenues in cAMP research. Nat. Rev. Mol. Cell Biol. 4:733-738.
6. Castro, A., M. J. Jerez, C. Gil, and A. Martinez. 2005. Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors. Med. Res. Rev. 25:229-244.
7. Chen, X. P., J. A. Losman, S. Cowan, E. Donahue, S. Fay, B. Q. Vuong, M. C. Nawijn, D. Capece, V. L. Cohan, and P. Rothman. 2002. Pim serine/threonine kinases regulate the stability of Socs-1 protein. Proc. Natl. Acad. Sci. USA 99:2175-2180.
8. Croker, B. A., D. L. Krebs, J. G. Zhang, S. Wormald, T. A. Willson, E. G. Stanley, L. Robb, C. J. Greenhalgh, I. Forster, B. E. Clausen, N. A. Nicola, D. Metcalf, D. J. Hilton, A. W. Roberts, and W. S. Alexander. 2003. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4:540-545.
9. Cullere, X., S. K. Shaw, L. Andersson, J. Hirahashi, F. W. Luscinskas, and T. N. Mayadas. 2005. Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase. Blood 105:1950-1955.
10. de Rooij, J., F. J. Zwartkruis, M. H. Verheijen, R. H. Cool, S. M. Nijman, A. Wittinghofer, and J. L. Bos. 1998. Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP. Nature 396:474-477.
11. 3-dependent endothelial cell adhesion, Rac-activation, and spreading through cAMP/PKA-dependent signaling. J. Biol. Chem. 277:45838-45846.
12. 4 integrin. J. Biol. Chem. 279:44889-44896.
13. 3 muscarinic acetylcholine receptor mediated by cyclic AMP and the GTPase Rap2B. J. Biol. Chem. 277:16805-16813.
14. 2B angiogenic phenotype. Hypertension 44:649-654.
15. Fukuhara, S., A. Sakurai, H. Sano, A. Yamagishi, S. Somekawa, N. Takakura, Y. Saito, K. Kangawa, and N. Mochizuki. 2005. Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway. Mol. Cell. Biol. 25:136-146.
16. Gasperini, S., L. Crepaldi, F. Calzetti, L. Gatto, C. Berlato, F. Bazzoni, A. Yoshimura, and M. A. Cassatella. 2002. Interleukin-10 and cAMP-elevating agents cooperate to induce suppressor of cytokine signaling-3 via a protein kinase A-independent signal. Eur. Cytokine Netw. 13:47-53.
17. Gupta, M., and S. J. Yarwood. 2005. MAP1A light chain 2 interacts with exchange protein activated by cyclic AMP 1 (EPAC1) to enhance Rap1 GTPase activity and cell adhesion. J. Biol. Chem. 280:8109-8116.
18. He, B., L. You, K. Uematsu, M. Matsangou, Z. Xu, M. He, F. McCormick, and D. M. Jablons. 2003. Cloning and characterization of a functional promoter of the human SOCS-3 gene. Biochem. Biophys. Res. Commun. 301:386-391.
19. Heinrich, P. C., I. Behrmann, S. Haan, H. M. Hermanns, G. Muller-Newen, and F. Schaper. 2003. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 374:1-20.
20. Holz, G. G. 2004. Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell. Diabetes 53:5-13.
21. Insel, P. A., and R. S. Ostrom. 2003. Forskolin as a tool for examining adenylyl cyclase expression, regulation, and G protein signaling. Cell. Mol. Neurobiol. 23:305-314.
22. Jee, S. H., C. Y. Chu, H. C. Chiu, Y. L. Huang, W. L. Tsai, Y. H. Liao, and M. L. Kuo. 2004. Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt pathways. J. Investig. Dermatol. 123:1169-1175.
23. Kamizono, S., T. Hanada, H. Yasukawa, S. Minoguchi, R. Kato, M. Minoguchi, K. Hattori, S. Hatakeyama, M. Yada, S. Morita, T. Kitamura, H. Kato, K. I. Nakayama, and A. Yoshimura. 2001. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2. J. Biol. Chem. 276:12530-12538.
24. 2+ release and exocytosis in pancreatic β-cells. J. Biol. Chem. 278:8279-8285.
25. s-coupled receptors. J. Biol. Chem. 279:46497-46508.
26. Kooistra, M. R., M. Corada, E. Dejana, and J. L. Bos. 2005. Epac1 regulates integrity of endothelial cell junctions through VE-cadherin. FEBS Lett. 579:4966-4972.
27. Kubo, M., T. Hanada, and A. Yoshimura. 2003. Suppressors of cytokine signaling and immunity. Nat. Immunol. 4:1169-1176.
28. Madamanchi, N. R., S. Li, C. Patterson, and M. S. Runge. 2001. Thrombin regulates vascular smooth muscle cell growth and heat shock proteins via the JAK-STAT pathway. J. Biol. Chem. 276:18915-18924.
29. Mahboubi, K., N. C. Kirkiles-Smith, J. Karras, and J. S. Pober. 2002. Desensitization of signaling by oncostatin M in human vascular cells involves cytoplasmic Tyr residue 759 in gp130 but is not mediated by either Src homology 2 domain-containing tyrosine phosphatase 2 or suppressor of cytokine signaling 3. J. Biol. Chem. 278:25014-25023.
30. Marin, V., F. A. Montera-Julian, S. Gres, V. Boulay, P. Bongrand, C. Farnarier, and G. Kaplanski. 2001. The IL-6-soluble IL-6Rα autocrine loop of endothelial activation as an intermediate between acute and chronic inflammation: an experimental model involving thrombin. J. Immunol. 167:3435-3442.
31. Morandini, R., G. Ghanem, A. Portier-Lemarie, B. Robaye, A. Renaud, and J. M. Boeynaems. 1996. Action of cAMP on expression and release of adhesion molecules in human endothelial cells. Am. J. Physiol. 270:H807-H816.
32. Mori, H., R. Hanada, T. Hanada, D. Aki, R. Mashima, H. Nishinakamura, T. Torisu, K. R. Chien, H. Yasukawa, and A. Yoshimura. 2004. SOCS3 deficiency in the brain elevates leptin sensitivity and confers resistance to diet-induced obesity. Nat. Med. 10:739-743.
33. Mountjoy, K. G., L. S. Robbins, M. T. Mortrud, and R. D. Cone. 1992. The cloning of a family of genes that encode the melanocortin receptors. Science 257:1248-1251.
34. Park, E. S., H. Kim, J. M. Suh, S. J. Park, O. Y. Kwon, Y. K. Kim, H. K. Ro, B. Y. Cho, J. Chung, and M. Shong. 2000. Thyrotropin induces SOCS-1 (suppressor of cytokine signaling-1) and SOCS-3 in FRTL-5 thyroid cells. Mol. Endocrinol. 14:440-448.
35. Rocchi, S., I. Gaillard, E. van Obberghen, E. M. Chambaz, and I. Vilgrain. 2000. Adrenocorticotrophic hormone stimulates phosphotyrosine phosphatase SHP2 in bovine adrenocortical cells: phosphorylation and activation by cAMP-dependent protein kinase. Biochem. J. 352:483-490.
36. Rogers, R. S., C. M. Horvath, and M. J. Matunis. 2003. SUMO modification of STAT1 and its role in PIAS-mediated inhibition of gene activation. J. Biol. Chem. 278:30091-30097.
37. Romano, M., M. Sironi, C. Toniatti, N. Polentarutti, P. Fruscella, P. Ghezzi, R. Faggioni, W. Luini, V. van Hinsbergh, S. Sozzani, F. Bussolino, V. Poli, G. Ciliberto, and A. Mantovani. 1997. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity 6:315-325.
38. Rui, L., M. Yuan, D. Frantz, S. Shoelson, and M. F. White. 2002. SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRS1 and IRS2. J. Biol. Chem. 277:42394-42398.
39. 2A adenosine receptor gene transfer. Mol. Pharmacol. 66:1147-1159.
40. Sasaki, A., K. Inagaki-Ohara, T. Yoshida, A. Yamanaka, M. Sasaki, H. Yasukawa, A. E. Koromilas, and A. Yoshimura. 2003. The N-terminal truncated isoform of SOCS3 translated from an alternative initiation AUG codon under stress conditions is stable due to the lack of a major ubiquitination site, Lys-6. J. Biol. Chem. 278:2432-2436.
41. Sasaki, A., H. Yasukawa, A. Suzuki, S. Kamizono, T. Syoda, I. Kinjyo, M. Sasaki, J. A. Johnston, and A. Yoshimura. 1999. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4:339-351.
42. Schieffer, B., T. Selle, A. Hilfiker, D. Hilfiker-Kleiner, K. Grote, U. J. Tietge, C. Trautwein, M. Luchtefeld, C. Schmittkamp, S. Heeneman, M. J. Daemen, and H. Drexler. 2004. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110:3493-3500.
43. Schmitz, J., M. Weissenbach, S. Haan, P. C. Heinrich, and F. Schaper. 2000. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 275:12848-12856.
44. Scholzen, T. E., C. Sunderkotter, D. H. Kalden, T. Brzoska, M. Fastrich, T. Fisbeck, C. A. Armstrong, J. C. Ansel, and T. A. Luger. 2003. Alpha-melanocyte stimulating hormone prevents lipopolysaccharide-induced vasculitis by down-regulating endothelial cell adhesion molecule expression. Endocrinology 144:360-370.
45. 2A-adenosine receptor in primary human endothelial cells. J. Biol. Chem. 272:5792-5799.
46. Shang, L., and T. B. Tomasi. 2006. The heat shock protein 90-CDC37 chaperone complex is required for signaling by types I and II interferons. J. Biol. Chem. 281:1876-1884.
47. Sjoholm, A., and T. Nystrom. 2005. Endothelial inflammation in insulin resistance. Lancet 365:610-612.
48. Sommer, U., C. Schmid, R. M. Sobota, U. Lehmann, N. J. Stevenson, J. A. Johnston, F. Schaper, P. C. Heinrich, and S. Haan. 2005. Mechanisms of SOCS3 phosphorylation upon interleukin-6 stimulation: contributions of Src- and receptor-tyrosine kinases. J. Biol. Chem. 280:31478-31488.
49. Steppan, C. M., J. Wang, E. L. Whiteman, M. J. Birnbaum, and M. A. Lazar. 2005. Activation of SOCS-3 by resistin. Mol. Cell. Biol. 25:1569-1575.
50. Stevenson, N. J., S. Haan, A. E. McClurg, M. J. McGrattan, M. A. Armstrong, P. C. Heinrich, and J. A. Johnston. 2004. The chemoattractants, IL-8 and formyl-methionyl-leucyl-phenylalanine, regulate granulocyte colony-stimulating factor signaling by inducing suppressor of cytokine signaling-1 expression. J. Immunol. 173:3243-3249.
51. Stoiber, D., P. Kovarik, S. Cohney, J. A. Johnston, P. Steinlein, and T. Decker. 1999. Lipopolysaccharide induces in macrophages the synthesis of the suppressor of cytokine signaling 3 and suppresses signal transduction in response to the activating factor IFN-γ. J. Immunol. 163:2640-2647.
52. Tanaka, T., M. A. Soriano, and M. J. Grusby. 2005. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity 22:729-736.
53. Tasken, K., and E. M. Aandahl. 2004. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol. Rev. 84:137-167.
54. Von der Thusen, J. H., J. Kuiper, T. J. van Berkel, and E. A. Biessen. 2003. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol. Rev. 55:133-166.
55. Wormald, S., and D. J. Hilton. 2004. Inhibitors of cytokine signal transduction. J. Biol. Chem. 279:821-824.
56. Yasukawa, H., M. Ohishi, H. Mori, M. Murakami, T. Chinen, D. Aki, T. Hanada, K. Takeda, S. Akira, M. Hoshijima, T. Hirano, K. R. Chien, and A. Yoshimura. 2003. IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nat. Immunol. 4:551-556.
57. York, R. D., H. Yao, T. Dillon, C. L. Ellig, S. P. Eckert, E. W. McCleskey, and P. J. Stork. 1998. Rap1 mediates sustained MAP kinase activation induced by nerve growth factor. Nature 392:622-626.
58. Zabeau, L., D. Lavens, F. Peelman, S. Eyckerman, J. Vandekerckhove, and J. Tavernier. 2003. The ins and outs of leptin receptor activation. FEBS Lett. 546:45-50.
59. Zhang, S. Q., W. G. Tsiaras, T. Araki, G. Wen, L. Minichiello, R. Klein, and B. G. Neel. 2002. Receptor-specific regulation of phosphatidylinositol 3′-kinase activation by the protein tyrosine phosphatase Shp2. Mol. Cell. Biol. 22:4062-4072.